Gilead Sciences (NASDAQ:GILD) Downgraded by Wall Street Zen to Buy

by · The Markets Daily

Gilead Sciences (NASDAQ:GILD – Get Free Report) was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a note issued to investors on Friday.

A number of other analysts also recently issued reports on the stock. Royal Bank Of Canada raised their price objective on shares of Gilead Sciences from $100.00 to $103.00 and gave the stock a “sector perform” rating in a report on Tuesday. Cantor Fitzgerald restated an “overweight” rating and set a $135.00 price target on shares of Gilead Sciences in a research note on Friday, October 31st. Mizuho lifted their price target on shares of Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. Morgan Stanley reduced their price objective on Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating for the company in a report on Tuesday, January 13th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $133.52.

Get Our Latest Stock Analysis on Gilead Sciences

Gilead Sciences Stock Performance

Shares of GILD stock traded up $4.79 during trading on Friday, hitting $135.93. The company’s stock had a trading volume of 13,178,890 shares, compared to its average volume of 5,442,228. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The company has a market cap of $168.65 billion, a PE ratio of 21.07, a P/E/G ratio of 0.69 and a beta of 0.33. The business has a fifty day moving average of $123.98 and a 200-day moving average of $118.62. Gilead Sciences has a 52 week low of $92.26 and a 52 week high of $136.30.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, research analysts anticipate that Gilead Sciences will post 7.95 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Deborah H. Telman sold 53,646 shares of the business’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the sale, the executive vice president directly owned 43,676 shares in the company, valued at approximately $5,365,596.60. The trade was a 55.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $125.86, for a total value of $3,524,080.00. Following the completion of the transaction, the insider owned 107,193 shares of the company’s stock, valued at approximately $13,491,310.98. This represents a 20.71% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 141,757 shares of company stock valued at $17,569,112 in the last 90 days. Corporate insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Several hedge funds have recently bought and sold shares of GILD. Personal CFO Solutions LLC boosted its holdings in Gilead Sciences by 1.7% in the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 76 shares during the period. SOA Wealth Advisors LLC. raised its position in shares of Gilead Sciences by 8.7% in the fourth quarter. SOA Wealth Advisors LLC. now owns 1,016 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 81 shares in the last quarter. Trivium Point Advisory LLC boosted its stake in Gilead Sciences by 1.1% during the third quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock valued at $813,000 after buying an additional 83 shares during the period. Binnacle Investments Inc grew its position in Gilead Sciences by 11.8% during the third quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company’s stock worth $87,000 after buying an additional 83 shares in the last quarter. Finally, Rothschild Investment LLC grew its position in Gilead Sciences by 1.9% during the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after buying an additional 84 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

(Get Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Read More